Drugs / CRISPR_SCD001
Trials 1
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 1/2 | NCT04774536 | Aug 2025 → Mar 2030 expected | sickle cell disease | Mark Walters, MD | Recruiting | No outcome recorded |
Evidence & citations 4 cited values
Every value below carries the sentence it was read from. 1 source stands behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | CRISPR_SCD001 | ClinicalTrials.gov intervention name — accepted as the source's own label NCT04774536 ↗ |
| Action | Restore | “CRISPRCas9 Corrected Hematopoietic Stem Cells” NCT04774536 ↗ |
| Modality | CRISPR / gene editing | “cells modified by the CRISPR-Cas9 ribonucleoprotein” NCT04774536 ↗ |
| Route | Intravenous | “administered by IV infusion” NCT04774536 ↗ |